No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Humanwell Healthcare (Group) Co.,Ltd. operates internationally, delivering a wide spectrum of healthcare solutions across regions including the Asia Pacific, North America, and Africa. The company's diverse product range features pharmaceuticals for pain management, such as anesthetics and analgesics, alongside a significant focus on women's health, providing items for reproductive planning, emergency contraception, and general wellness. They also produce central nervous system (CNS) medications addressing conditions like bronchitis, migraines, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, brain injuries, and peripheral vascular disorders. Furthermore, their offerings extend to traditional herbal remedies for common ailments such as colds and flu, rheumatoid arthritis, dermatological concerns, hepatitis, urinary tract infections, and memory impairment. Humanwell also supplies anti-infective agents, a variety of over-the-counter (OTC) drugs for digestive complaints, cold and flu relief, anti-inflammatory purposes, infections, and nutritional supplements. Complementing these, they offer specific treatments aimed at cardiovascular, gastrointestinal, and reproductive system diseases. Established in Wuhan, China, in 1993, the enterprise was initially known as Wuhan Humanwell Healthcare (Group) Co., Ltd. before adopting its current name, Humanwell Healthcare (Group) Co.,Ltd., in March 2013.
www.humanwell.com.cnNo one on the platform currently holds 600079.SS.
No tracked institution reports a position in 600079.SS as of their last filing.
No one on the platform has traded 600079.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.5% | 10.8% | — | — | — | |
| Rev. Growth % | -5.8% | 3.0% | ||||
| Profit Margin % | 7.7% | 7.8% | 5.5% | |||
| Free Cash Flow Margin % | 7.5% | 2.3% | 0.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $27.1B | +8.6% | $1.46 | $1.46–$1.46 | — | 1 |
| 2027 | $29.5B | +8.9% | $1.64 | $1.64–$1.64 | — | 1 |
| 2028 | $27.9B | -5.5% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600079.SSHumanwell Healthcare (Group) Co.,Ltd. | $18.50 | -0.22% | $30.2B | — |
| 000423.SZDong-E-E-Jiao Co.,Ltd. | $46.29 | +0.39% | $29.6B | — |
| 000513.SZLivzon Pharmaceutical Group Inc. | $26.62 | +0.15% | $23.6B | — |
| 002223.SZJiangsu Yuyue Medical Equipment & Supply Co., Ltd. | $26.07 | +2.24% | $26.1B | — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. |
| $21.65 |
| -0.64% |
| $22.0B |
| — |
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd | $19.13 | -0.16% | $17.6B | — |
| 002821.SZAsymchem Laboratories (Tianjin) Co., Ltd. | $177.55 | +0.20% | $59.1B | — |
Source: Financial Modeling Prep · peers by sector/industry